<DOC>
	<DOCNO>NCT00512902</DOCNO>
	<brief_summary>The purpose study assess safety tolerability imatinib ( gleevec ) subject systemic sclerosis . Imatinib approve FDA treatment newly diagnose adult patient CML ( newly diagnose adult patient treatment patient accelerate phase . Imatinib also approve treatment patient certain type gastrointestinal cancer ( call stromal tumor ) approve treat systemic sclerosis . Imatinib work interfere enzyme call tyrosine phosphatase result suppression immune system . It als interferes protein call platelet derive growth factor receptor ( PDGFr ) link increased fibrosis .</brief_summary>
	<brief_title>A Study Using The Experimental Drug Called Imatinib ( Gleevec ) Subjects With Systemic Sclerosis</brief_title>
	<detailed_description>Systemic sclerosis rare , progressive disease lead harden tighten skin connective tissue . It usually begin dry patch skin hand face begin get thicker harder . These patch spread area skin . In case , systemic sclerosis also affect blood vessel internal organ . Systemic sclerosis one group arthritic condition call connective tissue disorder , person 's antibody direct tissue .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . All patient must fulfill criterion SSc ACR criteria 2 . Age entry study ≥ 18 yr 3 . FVC &lt; 85 % predict . 4 . Able complete 6MWT walk distance ≥ 150 5 . Patients must dyspnea exertion ( grade ≥ 2 Magnitude Task component Mahler Modified Dyspnea Index ) . 6 . SSc ≤ 10 year , onset define date first nonRaynaud manifestation typical systemic sclerosis . 7 . Patients may limit ( cutaneous thicken distal proximal elbow knee , without facial involvement ) diffuse ( cutaneous thicken proximal elbow knee , often involve chest abdomen ) cutaneous SSc ( Medsger 1995 ) . 8 . Patients must show evidence alveolitis define HRCT lung show ground glass opacification radiographic marker `` alveolitis '' finely reticulate fibrosis must alveolitis BAL ( ≥ 3 % PMN 's ≥ 2 % eosinophil ) . 9 . Female patient childbearing potential must negative pregnancy test within 7 day initiation study drug dosing . 10 . Patients must able provide write voluntary informed consent . 1 . FVC ≤ 50 % predict DLCO ( correct Hgb alveolar volume ) ≤ 35 % predict ( suggest severe probably irreparable disease and/or significant pulmonary vascular involvement SSc ) . 2 . FEV1/FVC ratio &lt; 65 % ( exclude significant airflow obstruction ) 3 . Clinically significant abnormality HRCT attributable SSc ( e.g. , lung mass , extensive scarring due previous infection , etc . ) 4 . Clinically significant pulmonary hypertension document right heart catheterization ( i.e. , right ventricular systolic pressure &gt; 50 mm Hg and/or mean PAP ≥30 mm Hg ) pulmonary pressure echocardiographic evidence PAH ( echo cardiographic systolic pressure ≥ 55 mmHg ) FVC/DLCO ratio &gt; 1.6 pulmonary function test 5 . Persistent unexplained hematuria ( &gt; 10 RBCs/hpf ) . 6 . History persistent leukopenia ( white blood cell count &lt; 3500 ) , neutropenia ( absolute neutrophil count &lt; 1500 ) thrombocytopenia ( platelet count &lt; 100,000 ) . 7 . Clinically significant anemia ( &lt; 9.0 gm/dl ) 8 . Serum creatinine &gt; ULN . 9 . Pregnancy ( documented urine pregnancy test ) , breast feeding 10 . If childbearing potential , failure regularly employ reliable mean contraception 11 . Active infection lung elsewhere , whose management would compromise Imatinib 12 . Unreliability , drug abuse ( include active alcoholism ) 13 . Any chronic , debilitate illness ( SSc ) 14 . Smoking cigar , pipe cigarette past 6 month 15 . Baseline liver function test ( ALT AST bilirubin &gt; 1.5 x upper limit normal 16 . Previous use prednisone &gt; 10 mg per day . If prednisone ≤10 mg/d , dose must stable &gt; 1 month . 17 . All medication putative diseasemodifying property ( e.g. , Dpenicillamine , cyclophosphamide , azathioprine , methotrexate , colchicine , Potaba ) must discontinue 1 month prior begin study medication . 18 . Patient &lt; 5 year since she/he primary malignancy except : primary malignancy currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow except consultation PI . 19 . Patient Grade III/IV cardiac problem define New York Heart Association Criteria . ( i.e. , congestive heart failure , myocardial infarction within 6 month study ) 20 . Patient severe and/or uncontrolled medical disease ( i.e. , uncontrolled diabetes , chronic renal disease , active uncontrolled infection ) . 21 . Patient know chronic liver disease ( i.e. , chronic active hepatitis cirrhosis ) . 22 . Patient known diagnosis human immunodeficiency virus ( HIV ) infection . 23 . Use contraindicate medication baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>active alveolitis systemic sclerosis</keyword>
</DOC>